Giuliana Grossi

The United Nations 2030 Agenda for Sustainable Development has called for an end to violence against women in its Sustainable Development Goals.

Chair of the ACR COVID-19 Vaccine Clinical Guidance Task Force, Jeffrey Curtis, discusses the newest vaccine recommendations amid the Omicron variant.

Intravenous tramadol, developed by Avenue Therapeutics, fails to attain FDA approval as treatment for acute pain in adults.

Vibeke Strand explains that secukinumab improves psoriatic arthritis in patients regardless of their treatment history.

Progressive familial intrahepatic cholestasis is a genetic liver disease that doesn't only affect the children who are diagnosed, but also the caregivers responsible for them.

Phase 3 of the FUTURE 5 trial further examined the efficacious effect that secukinumab had on patients with psoriatic arthritis.

A new study highlights the urgency to implement better access and distribution of naloxone to avert witnessed opioid overdose deaths.

The CDC is encouraging public feedback on updated guideline recommendations for opioid prescribers for the first time since 2016.

Investigators developed a new method to identify potential treatments for hundreds of diseases by profiling drugs approved by the FDA.

Within the first year of the pandemic, total patients in the emergency department with a violent penetrating injury significantly increased—disproportionately so for people of color.

Experts explain that their analysis clearly lays out how lack of effective regulation and an unchecked profit motive created the opioid epidemic.

The fifth update from the American College of Rheumatology supports fourth doses of the vaccine for high-risk rheumatic disease patients.

The FDA was prompted to require a safety trial comparing tofacitinib with TNF inhibitors in patients with rheumatoid arthritis.

The recombinant von Willebrand factor, VONVENDI, receives approval from the FDA to treat patients living with severe type 3 von Willebrand disease.

Pfizer’s statement does not include a reason for the Complete Response Letter the FDA issued regarding the Biologics License Application for somatrogon for Pediatric Growth Hormone Deficiency.

The Carter Center announces that just 14 cases of Guinea worm disease occurred worldwide in 2021--the lowest case total ever recorded.

The findings of this study can be applied to guide opioid counseling and monitoring when prescribing the medication.

A new study evaluated factors associated with quality of life by observing levels of chronic pain in Chinese patients who were receiving maintenance hemodialysis.

A gene therapy for retinal degenerative diseases receives an investigational new drug (IND) clearance from the FDA to move forward with the Phase 2 trial of the multi-characteristic opsin (MCO-010) therapy.

In the midst of a national blood crisis, the FDA is funding a study to examine if different questioning can be used to determine the HIV risk of gay or bisexual men who want to donate blood.

New data show that even though physical therapy may be the more expensive treatment for knee osteoarthritis, it’s more effective than intra-articular glucocorticoid injection.

Contrary to recent research that indicated a higher risk of death associated with escalating doses of allopurinol for chronic kidney disease, investigators announce no association between allopurinol initiation and increased mortality among patients with gout and CKD.

Since an effective treatment for the rare disease metachromatic leukodystrophy had not previously been distinguished, investigators analyzed data on the safety and efficacy of arsa-cel, a gene therapy.

While Omicron cases surge, Valentina, Baez-Sosa, MD, speaks on the national blood shortage and the risk it poses to patients with sickle cell disease in particular.

Maureen Achebe goes into detail about the open label extension of the HOPE trial that evaluated to use of Voxelotor in patients with sickle cell disease and anemia.

As the year begins, Edward Ivy addresses what's currently happening in the field of sickle cell disease from the impact of the blood shortage to exciting new therapies.

Alloimmunization is more prevalent among patients with sickle cell disease than previous literature states. Baez-Sosa discusses her study and treatment practices.

Promising results were announced by UCB after a Phase 3 study evaluated bimekizumab for non-radiographic axial spondyloarthritis and met all endpoints.

After conducting and extensive literary review on all eligible data regarding COVID-19 in patients with sickle cell disease or trait, experts discuss what is known and what needs to be better understood about the pandemic's effect on this population.

Investigators conducted an extensive literature review on clinical COVID-19 outcomes in patients with SCD or SCT to better navigate treatment during the pandemic.